

A Trusted Path to Outstanding Outcomes



Deep skin resurfacing

Courtesy of Suzanne L. Kilmer, MD




Before

After

Periorbital skin resurfacing

Courtesy of J. Kevin Duplechain, MD



Before

After

Scar revision

Courtesy of Jill S. Waibel, MD



Before

After

Scar revision

Courtesy of Jill S. Waibel, MD



Before

After

"I feel that I can safely treat my patients more aggressively with the UltraPulse, something I would not attempt with other CO₂ laser systems"

—

Dr. Girish Munavalli, Dermatologist

"With UltraPulse's SCAAR FX, I am able to treat deep skin conditions, like hypertrophic scars, with the results of enhanced skin condition and improved quality of life for patients. SCAAR FX has the unique combination of short pulse durations and high energy which enables deep, precise and effective treatment."

—

Dr. Matteo Tretti Clementoni, Plastic Surgeon

Specifications

Indication	UltraPulse®
PLATFORM	UltraPulse® DeepFX™, ActiveFX™, TotalFX™
Technical Specifications	
Wavelength	10,600 nm
Laser Type	UltraPulse® and CW
Power to Tissue	60 W
Peak Power	240 W
Spot Size	min. 0.12 mm / max. 2.0 mm TrueSpot™
Scan Size	Up to 15 x 15 mm
Density per Scan	fractional: 1-82%, full ablative: >100%
Full Resurfacing Capabilities	yes
Fractional Capabilities	yes
Incisional Capabilities	yes
Excisional Capabilities	yes
Aiming Beam	5 mW red diode laser, 635 nm, adjustable intensity
Beam Delivery	Articulated arm w/240 cm (94.5 in) reach, 360° rotation
Memory Setting	3
Cooling	Self-contained, closed cycle
Warranty and Coverage	1 Year standard
Recommended Passes/Treatment	1
Platform Specifications	
Electrical	100–240 VAC, 20 A max., 50/60 Hz
Weight	128 kg (280 lbs)
Dimensions (WxDxH)	34 cm x 51 cm x 144-195 cm (13.6 x 20 x 57-77 in)

© 2017 All Rights Reserved. The Lumenis Group of Companies. Lumenis, its logo, UltraPulse, AcuPulse, ActiveFX, DeepFX, TotalFX and SCAAR FX are trademarks or registered trademarks of the Lumenis Group of Companies. Specifications are subject to change without notice. Lumenis is ISO 13485:2003 certified. UltraPulse is CE approved. | UltraPulse is FDA cleared. PB-1124760 Rev D.



 Lumenis Ltd.
Yokneam Industrial Park
6 Hakidma Street P.O.B. 240
Yokneam 2069204, Israel
Tel: +972-4-959-9000

 Lumenis (Germany) GmbH
Heinrich-Hertz-Str 3 D-63303
Dreieich-Dreieichenhain
GERMANY
Tel: +49 (0) 6103 8335 0

EMEA
Dreieich Dreieichenhain,
Germany
T +49 6103 8335 0
F +49 6103 8335 300

Roma, Italy
T +39 06 90 75 230
F +39 06 90 75 269
Hertfordshire, UK
T +44 20 8736 4110
F +44 20 8736 4119

JAPAN
Tokyo, Japan
T +81 3 6743 8300
F +81 3 6743 8301

AMERICAS
San Jose, CA, USA
T +1 408 764 3000
+1 877 586 3647
F +1 408 764 3999

ASIA PACIFIC
Beijing, China
T +86 10 5737 6677
F +86 10 5737 6767
Gurgaon, India
T +91 124 422 07 95
Kowloon, Hong Kong
T +852 217 428 00
F +852 272 251 51

 **0473** Rx ONLY

UltraPulse®

The most powerful
CO₂ laser in
aesthetic medicine



UltraPulse®

The most powerful CO₂ laser in aesthetic medicine

Stretching the limits of performance

UltraPulse® can penetrate deeper than any aesthetic CO₂ laser. Combined with great versatility, this makes UltraPulse® perfect for both everyday procedures and the thick and complex lesions.



DeepFX™ | ActiveFX™ Fractional Modes

- Great versatility and precision for all your resurfacing needs
- CoolScan™ technology for enhanced patient comfort

Deepest Impact with SCAAR FX™ Mode

- Up to 4mm in a single pulse
- Ideal mode for treating deep, thick lesions

Exceptional Ablation/Coagulation Ratio












- Optimal clinical outcomes with minimal excess heating
- Proven efficacy in dozens of clinical studies and peer-reviewed publications

Shortest Pulse Duration

- Faster than the tissue relaxation time
- Minimizing thermal damage

Highly Advanced Scanners

For Maximum Versatility, Speed and Efficacy


UltraPulse® Configuration	Treatment Mode	Description	Spot Size and Distribution
DeepFX™ 	DeepFX™	Deep impact for treating wrinkles, acne scars and other deep cosmetic lesions	 0.12 mm
	SCAAR FX™	Deepest impact in a single pulse for treating thick, complex lesions	
ActiveFX™ 	PigmentFX™	Low, sub-ablative fluence for mild treatment of dyschromia	  1.3 mm
	ActiveFX™/ MaxFX™	Wide range of settings, including the CO ₂ Lite™, ActiveFX Gentle™, ActiveFX™ and MaxFX™ modes, for full and fractional treatment of texture and pigment inconsistencies	
TotalFX™ 	All of the above	A full range of treatment possibilities, from mildest to the most aggressive – all in one	 0.12 mm and 1.3 mm
Any 	PreciseFX™	Collimated 2.0mm handpiece for fast and precise tissue ablation and coagulation with consistent fluence	 2.0 mm
Any 	IncisionFX™	0.2mm focused handpiece for clean, precise incisions	 0.2 mm

UltraPulse®

State of The Art Technology


UltraPulse®

- Highest peak power
- Deepest impact
- Narrow, controlled thermal zone



Continuous Wave (CW)

- Low peak power
- Superficial impact
- Wider thermal zone




Exceptional ablation/coagulation ratio

When ablation depth is equal, more energy means more excess heat in the tissue. UltraPulse® technology enables the deepest penetration with the lowest energy. This reduces patient discomfort, downtime and thermal damage.

UltraPulse® also enables the shortest pulses per energy level further enhancing patient comfort.

Warnings and risks

CO₂ lasers are intended solely for use by physicians trained in the use of the Carbon Dioxide laser (10.6 µm) wavelength. Incorrect treatment settings or misuse of the technology can present risk of serious injury to patient and operating personnel. Risks that may be associated with any CO₂ laser procedure may include change of pigmentation, infection, erythema, skin induration or scarring. Read and understand the CO₂ systems and accessories operator manuals for a complete list of intended use, contraindications and risks. The use of Lumenis® CO₂ laser is contraindicated where a patient has taken Accutane (Isotretinoin) within the past 6-12 months, has a history of keloid formation and demonstrate excessive or unusually prolonged erythema.



- UltraPulse
- AcuPulse
- Competitor 1
- Competitor 2
- Competitor 3